Company news
Vivoryon Therapeutics N.v. (EURONEXT:VVY) news
Every Vivoryon Therapeutics N.v. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
August 18, 2026
Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for...
July 22, 2026
Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026
June 8, 2026
Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update
April 23, 2026
Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026
April 15, 2026
Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference
April 9, 2026
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at Worl...
March 28, 2026
Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
January 7, 2026
Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates
December 4, 2025
Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025
November 25, 2025
Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025
November 6, 2025
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences
November 3, 2025
Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million
October 7, 2025
Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million
October 6, 2025
Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates
September 4, 2025
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025
August 27, 2025
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences
June 27, 2025
Vivoryon Therapeutics N.V. Reports Outcome of 2025 Annual General Meeting
June 24, 2025
Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress
June 17, 2025
Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025
June 11, 2025
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025
June 6, 2025
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat
May 27, 2025
Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meeting on June 24, 2025
May 13, 2025
Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update
April 29, 2025
Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million
April 24, 2025